Phase 3 Clinical Trials With Primary Completion Dates in December 2017

This is a list of Phase 3 trials with primary completion dates in December 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACADACADIA Pharmaceuticals Inc.2017-12-01Phase 3NCT00550238A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
ALKSAlkermes plc2017-12-01Phase 3NCT02141399A Long-Term Safety Study of ALKS 5461
AMRNAmarin Corporation plc2017-12-01Phase 3NCT01492361A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
AQXPAquinox Pharmaceuticals, Inc.2017-12-01Phase 3NCT02858453Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
ARGSArgos Therapeutics, Inc.2017-12-01Phase 3NCT01582672Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
AXSMAxsome Therapeutics, Inc.2017-12-01Phase 3NCT02504008CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
CERSCerus Corporation2017-12-01Phase 3NCT01740531Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
CTRVContraVir Pharmaceuticals Inc2017-12-01Phase 3NCT02412917A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
CVMCel-Sci Corporation2017-12-01Phase 3NCT01265849Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
DEPODepomed, Inc.2017-12-01Phase 3NCT02081391An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants
EARSAuris Medical Holding AG2017-12-01Phase 3NCT02040194AM-101 in the Treatment of Acute Tinnitus 3
ENDPEndo International plc2017-12-01Phase 3NCT01210352Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
EYEGEyegate Pharmaceuticals, Inc.2017-12-01Phase 3NCT02517619Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
INSYInsys Therapeutics, Inc.2017-12-01Phase 3NCT02318602Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
INSYInsys Therapeutics, Inc.2017-12-01Phase 3NCT02138409Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting
KERXKeryx Biopharmaceuticals, Inc.2017-12-01Phase 3NCT02492620Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
MDMednax, Inc2017-12-01Phase 3NCT02534077Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
MESOMesoblast Limited2017-12-01Phase 3NCT02336230A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
MMSIMerit Medical Systems, Inc.2017-12-01Phase 3NCT01387932HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
NBRVNabriva Therapeutics plc2017-12-01Phase 3NCT02813694Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
NKTRNektar Therapeutics2017-12-01Phase 3NCT02367820Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
OHRPOhr Pharmaceuticals, Inc.2017-12-01Phase 3NCT02727881Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
ONTXOnconova Therapeutics, Inc.2017-12-01Phase 3NCT01928537Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
PENPenumbra, Inc.2017-12-01Phase 3NCT01636453The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms
PTCTPTC Therapeutics, Inc.2017-12-01Phase 3NCT02090959Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
PTCTPTC Therapeutics, Inc.2017-12-01Phase 3NCT01557400Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada
RVNCRevance Therapeutics, Inc.2017-12-01Phase 3NCT03014635Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
RVNCRevance Therapeutics, Inc.2017-12-01Phase 3NCT03014622Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
SGENSeattle Genetics, Inc.2017-12-01Phase 3NCT01777152ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
SNGXSoligenix, Inc.2017-12-01Phase 3NCT02448381FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
SPPISpectrum Pharmaceuticals, Inc.2017-12-01Phase 3NCT02953340Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)
TTPHTetraphase Pharmaceuticals, Inc.2017-12-01Phase 3NCT02784704Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
VBLTVascular Biogenics Ltd.2017-12-01Phase 3NCT02511405A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
VTLVital Therapies, Inc.2017-12-01Phase 3NCT02612428Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD